FRACTYL HEALTH, INC. COMMON STOCK

NASDAQ: GUTS (Fractyl Health, Inc.)

Kemas kini terakhir: 23 Jun, 5:44PM

1.61

-0.53 (-24.77%)

  • 1H -24.77%
  • 5H 57.84%
  • 1B 61.00%
  • 6B 23.85%
  • Tahun Ke Tarikh -24.41%
  • 1T -36.61%
  • 5T -87.47%
Penutupan Terdahulu 2.14
Buka 1.75
Jumlah Dagangan 6,190,853
Purata Dagangan (3B) 302,703
Modal Pasaran 78,852,328
Harga / Jualan (P/S) 2.83
Harga / Buku (P/B) 1.86
Julat 52 Minggu
0.873 (-45%) — 5.00 (210%)
Tarikh Pendapatan 13 Aug 2025
Margin Operasi (TTM) -161,246.67%
EPS Cair (TTM) -1.94
Pertumbuhan Hasil Suku Tahunan (YOY) -57.10%
Jumlah Hutang/Ekuiti (D/E MRQ) 963.53%
Nisbah Semasa (MRQ) 2.50
Aliran Tunai Operasi (OCF TTM) -78.89 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -47.87 M
Pulangan Atas Aset (ROA TTM) -49.05%
Pulangan Atas Ekuiti (ROE TTM) -196.81%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menurun
Biotechnology (Global) Bercampur Menurun
Stok Fractyl Health, Inc. Menurun Menurun

AISkor Stockmoo

-0.3
Konsensus Penganalisis 3.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal -2.0
Purata -0.25

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
GUTS 79 M - - 1.86
BNTX 23 B - - 1.08
IMCR 2 B - - 4.46
GPCR 1 B - - 1.76
ZBIO 798 M - - 3.21
SEPN 642 M - - 1.85

Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 4.84%
% Dimiliki oleh Institusi 82.39%

Pemilikan

Nama Tarikh Syer Dipegang
Hcc Manager Llc 31 Mar 2025 4,673,871
19.2019.2015.6015.6012.0012.008.408.404.804.80Harga Sasaran MedianQ1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25Q3 '25Q3 '25
Julat 52 Minggu
0.873 (-45%) — 5.00 (210%)
Julat Harga Sasaran
3.60 (123%) — 9.00 (459%)
Tinggi 9.00 (HC Wainwright & Co., 459.01%) Beli
Median 6.00 (272.67%)
Rendah 3.60 (Ladenburg Thalmann, 123.60%) Beli
Purata 6.20 (285.09%)
Jumlah 3 Beli
Harga Purata @ Panggilan 0.983
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 15 Sep 2025 9.00 (459.01%) Beli 0.982
Ladenburg Thalmann 28 Aug 2025 3.60 (123.60%) Beli 0.990
Canaccord Genuity 14 Aug 2025 6.00 (272.67%) Beli 0.977

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
03 Sep 2025 Pengumuman Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth
12 Aug 2025 Pengumuman Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates
07 Aug 2025 Pengumuman Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
06 Aug 2025 Pengumuman Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference
06 Aug 2025 Pengumuman Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering
05 Aug 2025 Pengumuman Fractyl Health Announces Proposed Public Offering
05 Aug 2025 Pengumuman Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure
23 Jun 2025 Pengumuman Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
23 Jun 2025 Pengumuman Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
1.101.101.041.040.9910.9910.9370.9370.8830.883Sep 10Sep 10Sep 11Sep 11Sep 12Sep 12Sep 15Sep 15Sep 16Sep 16Sep 17Sep 17Sep 18Sep 18Sep 19Sep 19

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
-0.000-0.000-0.100-0.100-0.200-0.200-0.300-0.300-0.400-0.400MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda